Insights & news

European Parliament adopts Health Technology Assessment Regulation

  • 08/10/2018
  • Articles

On 3 October 2018, the European Parliament adopted with a large majority the proposed Regulation on Health Technology Assessment (“HTA”) (the “Regulation” - see also our  article of 1 February 2018).

The initiative on HTA cooperation at the European level had generally been well received in January 2018 when the European Commission first issued its proposal. However, several Member States (such as Germany) questioned the Regulation’s compatibility with the subsidiarity principle and objected to the mandatory uptake of the joint HTA reports and to the oversight to be exercised by the European Commission. National and regional HTA agencies also voiced concerns  over the increased workload that would be caused for them and flagged the need for more robust guarantees to avoid publication and reporting bias by health technology developers.

The amended Regulation as adopted by the European Parliament has given rise to a new flurry of criticism. In particular, patients, together with some left-leaning parties, regret that they were not given a concrete role in the decision-making process along with scientific experts, despite a proposed amendment to that effect. Instead, these stakeholders are only given the right to submit written comments. Similarly, healthcare professionals are as yet not included in the HTA process.

For its part, MedTech Europe raised concerns regarding the inclusion of specific medical devices in the scope of the Regulation at a time when that industry is already spending substantial resources on compliance with the new EU Medical Devices Regulations. MedTech Europe also advocates allowing Member States with similar needs to conduct voluntary joint HTA.

The European Parliament accommodated a major wish of a group of Member States by changing the threshold for the Coordination Group’s decisions from a two-thirds to a qualified majority. That Coordination group, composed of representatives from Member States’ HTA authorities and bodies, is the body entrusted with overseeing joint clinical assessments and other joint work under the Regulation. In addition, national and regional HTA agencies would be entitled to carry out their own additional clinical assessments which they consider necessary to complete the HTA or the overall pricing and reimbursement process on condition that these assessments are “justified, necessary and proportionate”, do not duplicate work carried out at Union level and do not unduly delay patient access to those technologies. However, this attempt to placate certain Member States seems at odds with the harmonisation purpose of the Regulation, which industry (e.g. EFPIA) has been quick to point out.

It remains to be seen how the Regulation will fare before the Council. It seems unlikely at this stage that the legislative process will be completed before the European Parliament elections in May 2019.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 18/07/2019
    • Articles

    Transatlantic Cooperation on Medicines - Latest Developments

    A visit to Canada by the Dutch Minister for Medical Care, Bruno Bruins, has given rise to interesting news regarding international cooperation on medicine pricing. According to the attached press release of 17 July 2019, The Netherlands is spearheading an effort to have Canada sign up to the Beneluxa initiative on medicines (http://www.beneluxa.org/). Beneluxa is an international alliance for pharmaceutical policy composed of Austria, Belgium, Ireland, Luxembourg and The Netherlands. Medicine pricing is one of the pillars of Beneluxa along with other areas such as horizon scanning. A possible transatlantic contribution to Beneluxa by Canada would undoubtedly add considerable economic weight to the grouping and to the pricing negotations which it initiates. At the same time, it would create a further layer of technical complexity that may cause an already cumbersome organisation to become entirely unwieldy. Separately, Canada also wants to participate in the International Horizon Scanning Initiative (“IHSI”) in which countries from the Beneluxa group and others seek to identify innovative medicines before they reach the market. The initiative is supposed to inform decision-making on treatment choices and prepare members for tough budgetary discussions. An announcement on the countries that will participate in IHSI is scheduled for October 2019.

    Read more
    • 15/07/2019
    • Articles

    Belgium - Request for Premiums and Benefits by Hospitals from Suppliers of Medicines and Medical Devices in Public Procurement Proceedings

    The Federal Agency for Medicines and Health Products (“FAMHP”) has recently come out against hospitals requesting premiums and benefits from firms participating in tender proceedings for the supply of medicines and/or medical devices. According to FAMHP, that practice is not only prohibited by Article 81 of the Law of 17 June 2016 on Public Procurement, but may also run foul of Article 10 of the Law of 25 March 1964 regarding Medicines. At issue is the widespread practice indulged in by hospitals to ask prospective suppliers of medicines or medical devices to take care of unrelated goods and services such as the supply of educational materials and software for patient management or to pay for outreach activities organised by the hospitals. Article 81 of the Law of 17 June 2016 on Public Procurement provides in relevant part that the award criteria of a request for tenders should be connected to the subject of the public procurement procedure. For its part, Article 10 of the Law of 25 March 1964 regarding Medicines prohibits firms, subject to exceptions, from offering or providng benefits in cash or in kind to specific healthcare professionals and institutions in connection with the prescription, administration or supply of medicines or medical devices. Similarly, healthcare professionals and institutions are banned from soliciting or receiving such benefits. Based on a combined reading of these provisions, FAMHP maintains that it is not possible to offer or request free additional services with the supply of medicines or medical devices. According to FAMHP, additional services have to (i) come at a price; or (ii) and this is a puzzling addition, “have to present a cost which expressly forms part of the price of the goods”. Importantly, the services have to present a connection with the goods supplied. FAMHP indicates that this implies that outreach activities or additional software are “not admissible”. It adds that “free competition” should be guaranteed at all times and that a hospital should be able to justify the use of a specific award criterion. In other words, the hospital does not benefit from discretionary powers when crafting and then implementing a procurement procedure. Attached are a circular letter of FAMHP on the subject as well as an opinion delivered earlier this year by the committee for public procurement, an advisory body, which informed the point of view of FAMHP.

    Read more
    • 12/07/2019
    • Articles

    Slovakia Final Member State To Benefit From EU-US Mutual Recognition Agreement For Inspections of Manufacturing Sites For Human Medicines

    Slovakia has become the 28th and final EU Member State to be given the powers to carry out good manufacturing practice (“GMP”) inspections at a level equivalent to that prevailing in the US (see attached press release). On 11 July 2019, the US Food and Drug Administration (“FDA”) confirmed Slovakia’s status under the Mutual Recognition Agreement (“MRA”) governing GMP inspections of manufacturing sites for human medicines between the EU and the US. For their part, EU Member States have been able to rely on inspection results produced by the FDA since 1 November 2017. Pursuant to the MRA, the EU and the US now fully recognise inspections of manufacturing sites for human medicines carried out in each other’s territories. Separately, the batch testing waiver existing under the MRA will also start to apply. As a result, qualified persons in pharmaceutical firms based in Europe will no longer be required to carry out the quality controls when these have already been run in the US. The EU and US will continue implementation work for the MRA in hopes of extending its scope to a range of additional products, including veterinary medicines, human vaccines and plasma derived medicinal products.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *